Elite in Multiple Myeloma

Dr. Sundar Jagannath

Oncology
Icahn School Of Medicine At Mount Sinai
5 E 98th St, Suite 6, 
New York, NY 
Offers Telehealth
44 Years of Experience
Elite in Multiple Myeloma
Icahn School Of Medicine At Mount Sinai
5 E 98th St, Suite 6, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sundar Jagannath is an Oncologist in New York, New York. Dr. Jagannath has been practicing medicine for over 44 years and is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Plasmacytoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 236 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 221 articles and participated in 6 clinical trials in the study of Multiple Myeloma.

Specialties
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Mount Sinai Beth Israel
Mount Sinai Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
5 E 98th St, Suite 6, New York, NY 10029

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase II Trial of Isatuximab (SAR650984) With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
Phase II Trial of Isatuximab (SAR650984) With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Other, Biological
Study Drug: Isatuximab
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Drug
Study Drugs: TAK-079, Pomalidomide, Dexamethasone
Study Phase: Phase 1/Phase 2
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Biological
Study Drug: CAR2 Anti-CD38 A2 CAR-T Cells
Study Phase: Phase 1
View 6 Less Clinical Trials

236 Total Publications

Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.
Journal: The New England journal of medicine
Published: August 20, 2025
Similar Doctors
Elite in Multiple Myeloma
Dr. David S. Siegel
Oncology | Hematology
Elite in Multiple Myeloma
Dr. David S. Siegel
Oncology | Hematology

Regional Cancer Care Associates LLC

92 2nd St, 
Hackensack, NJ 
 (8.4 miles away)
201-996-5900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Siegel is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Siegel is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Plasmacytoma, and Bone Marrow Transplant.

Elite in Multiple Myeloma
Dr. Joshua R. Richter
Oncology | Hematology
Elite in Multiple Myeloma
Dr. Joshua R. Richter
Oncology | Hematology

Icahn School Of Medicine At Mount Sinai

1 Gustave L Levy Pl, 
New York, NY 
 (0.2 miles away)
212-731-7650
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Richter is an Oncologist and a Hematologist in New York, New York. Dr. Richter is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Secondary Immunodeficiency (SID), Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Multiple Myeloma
Dr. Sham Mailankody
Oncology | Hematology
Elite in Multiple Myeloma
Dr. Sham Mailankody
Oncology | Hematology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (1.5 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sham Mailankody is an Oncologist and a Hematologist in New York, New York. Dr. Mailankody is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jagannath's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile